Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines

Breast cancer has for long been recognized as a highly diverse tumor group, but the underlying genetic basis has been elusive. Here, we report an extensive molecular characterization of a collection of 41 human breast cancer cell lines. Protein and gene expression analyses indicated that the collection of breast cancer cell lines has retained most, if not all, molecular characteristics that are typical for clinical breast cancers. Gene mutation analyses identified 146 oncogenic mutations among 27 well-known cancer genes, amounting to an average of 3.6 mutations per cell line. Mutations in genes from the p53, RB and PI3K tumor suppressor pathways were widespread among all breast cancer cell lines. Most important, we have identified two gene mutation profiles that are specifically associated with luminal-type and basal-type breast cancer cell lines. The luminal mutation profile involved E-cadherin and MAP2K4 gene mutations and amplifications of Cyclin D1, ERBB2 and HDM2, whereas the basal mutation profile involved BRCA1, RB1, RAS and BRAF gene mutations and deletions of p16 and p14ARF. These subtype-specific gene mutation profiles constitute a genetic basis for the heterogeneity observed among human breast cancers, providing clues for their underlying biology and providing guidance for targeted pharmacogenetic intervention in breast cancer patients.

[1]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[2]  M. Skolnick,et al.  Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. , 1997, Cancer research.

[3]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[4]  J. Minna,et al.  Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. , 1998, Cancer research.

[5]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[6]  S. Jeffrey,et al.  Basal carcinoma of the breast revisited: an old entity with new interpretations , 2008, Journal of Clinical Pathology.

[7]  A. Børresen-Dale,et al.  TP53 and breast cancer , 2003, Human mutation.

[8]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[10]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[11]  Mieke Timmermans,et al.  How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study , 2005, Clinical Cancer Research.

[12]  S. Sukumar,et al.  Mutations in p53 as potential molecular markers for human breast cancer. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Heinz Höfler,et al.  Mutations of the human E‐cadherin (CDH1) gene , 1998, Human mutation.

[14]  Scott E Kern,et al.  Focus on pancreas cancer. , 2002, Cancer cell.

[15]  L. Saal,et al.  Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair , 2008, Nature Genetics.

[16]  Hanina Hibshoosh,et al.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.

[17]  Karla Kerlikowske,et al.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. , 2007, Cancer cell.

[18]  A. Hollestelle,et al.  BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. , 2006, Cancer research.

[19]  D. Easton,et al.  Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast , 2006, Histopathology.

[20]  Chad J. Creighton,et al.  MDA-MB-435 cells are derived from M14 Melanoma cells––a loss for breast cancer, but a boon for melanoma research , 2007, Breast Cancer Research and Treatment.

[21]  I. Bièche,et al.  Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer , 2000, Molecular carcinogenesis.

[22]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[23]  J. Foekens,et al.  The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine. , 2008, Drug discovery today.

[24]  R. Lidereau,et al.  Point mutation at codon 12 of the Ki-ras gene in a primary breast carcinoma and the MDA-MB-134 human mammary carcinoma cell line. , 1990, Cancer letters.

[25]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[26]  D. Barnes,et al.  Cyclin D1 in Breast Cancer , 2004, Breast Cancer Research and Treatment.

[27]  D Pinkel,et al.  Mechanisms of inactivation of E-cadherin in breast cancer cell lines. , 1998, Cancer research.

[28]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[29]  K. Shokat,et al.  PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. , 2008, Cancer research.

[30]  J. Reis-Filho,et al.  Basal-like breast cancer and the BRCA1 phenotype , 2006, Oncogene.

[31]  S. Kern,et al.  Mutation rate of MAP2K4/MKK4 in breast carcinoma , 2002, Human mutation.

[32]  Tom Walsh,et al.  Ten genes for inherited breast cancer. , 2007, Cancer cell.

[33]  A. Chambers,et al.  MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? , 2009, Cancer research.

[34]  C. Sherr Divorcing ARF and p53: an unsettled case , 2006, Nature Reviews Cancer.

[35]  T. Crook,et al.  TP53 mutations in familial breast cancer: Functional aspects , 2003, Human mutation.

[36]  H Clevers,et al.  Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. , 2001, Cancer research.

[37]  Mieke Schutte,et al.  Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines , 2007, Molecular Cancer Research.

[38]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[39]  S. Merajver,et al.  Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines , 2008, Breast Cancer Research and Treatment.

[40]  E. Paish,et al.  Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression , 2007, Histopathology.

[41]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[42]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[43]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[44]  J. Roth,et al.  Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium. , 1976, Cancer research.

[45]  D. Tong,et al.  Comparison of p53 Mutational Status with mRNA and Protein Expression in a Panel of 24 Human Breast Carcinoma Cell Lines , 2003, Breast Cancer Research and Treatment.

[46]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[47]  R. Marais,et al.  Melanoma biology and new targeted therapy , 2007, Nature.

[48]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Klijn,et al.  Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines , 2006, Breast Cancer Research and Treatment.